To the Editor:

Prone position ventilation has been shown to improve oxygenation and survival in patients with severe acute respiratory distress syndrome (ARDS) \[[@CR1]\]. Facing the coronavirus disease 2019 (COVID-19) pandemic, prone positioning (PP) is of crucial importance to treat severe ARDS patients \[[@CR2]\]. Nevertheless, the high number of ICU admissions quickly overwhelmed the ability of the daily ICU team to place patients in PP, a complex and time-consuming maneuver. Thus, we created a dedicated medical team with reassigned volunteers to cope with the large number of patients requiring PP.

PP Team consisted of five volunteers: a senior medical non-intensivist physician placed at the patient's head to secure the endotracheal tube and four medical fellows or medical students placed at each side of the bed. For patients treated with VV-ECMO, a supplementary physician was added to secure the lines. Since PP is a complex procedure and has many potential adverse events requiring adequate and well-trained staff, volunteers received previously a theoretical training and a hands-on ad hoc training session. PP teams followed the guidelines for PP placement \[[@CR1]\].

This retrospective observational study was performed in our extended ICU (from 22 to 46 beds), from the first day of deployment of PPT (March 23 to April 23, 2020).

The main characteristics and outcomes of prone positioned patients (*n* = 63) are presented in Table [1](#Tab1){ref-type="table"}. A total of 367 placements in a prone or supine position were performed during the 1-month study period (Table [2](#Tab2){ref-type="table"}). Table 1Initial characteristics and outcome of the prone positioned ARDS COVID-19 population (data are expressed as median (interquartile range, IQR) or number (%) as appropriate. After visual assumption of normality, Wilcoxon rank tests were applied for continuous variables. For categorical variables, Fisher's exact or chi^2^ tests were applied as appropriate)Variables***n***, total availableTotal, ***n***(%) or median (IQR) (***n*** = 63)***n***, available for ICU survivors (***n*** = 46) \*ICU survivors, ***n***(%) or median (IQR) \****n***, available for ICU non-survivors (***n*** = 16)\*ICU non-survivors, ***n***(%) or median (IQR) \****p*Demographic data** Female ratio6315 (24%)4610 (22%)165 (31%)0.50 Age (years)6364 (56--70)4662 (54--69)1667 (64--74)0.045 Weight (kg)6189 (75--103)4590 (80--103)1589 (73--106)0.68 Body mass index (kg/m^2^)6130 (25--36)4530 (26--35)1529 (25--46)0.87 SAPS II6342 (31--57)4637 (27--57)1646 (42--59)0.030**Medical history** Diabetes mellitus6317 (27%)4611 (24%)165 (31%)0.74 Hypertension6330 (48%)4619 (41%)1610 (62%)0.14 Chronic respiratory disease6316 (25%)4613 (28%)163 (19%)0.53 Chronic immunosuppression†635 (8%)462 (4%)163 (19%)0.10 Chronic Cardiovascular disease6316 (25%)4612 (26%)163 (19%)0.74 Chronic kidney disease633 (5%)462 (4%)161 (6%)1.00**Respiratory parameters** Static compliance (ml/cmH~2~O) before first prone positioning4633 (23--42)3535 (27--44)1122 (18--36)0.036 PaO~2~/F~I~O~2~ ratio before first prone positioning6392 (70--117)4696 (70--120)1686 (64--111)0.54 Number of prone positioning per patient633 (2--6)463 (2--6)164 (3--8)0.19**Events in ICU** Vasopressors administered6338 (60%)4623 (50%)1614 (88%)0.008 VV-ECMO6314 (22%)4611 (24%)163 (19%)1.00 Renal replacement therapy638 (13%)464 (9%)164 (25%)0.19 ICU length of stay (days)6219 (14--31)4620 (15--32)1616 (12--28)0.24^\*^1 patient still in ICU^†^Representing active cancer medical history or chronic immunosuppressor therapiesTable 2Prone and supine placements and reported adverse events during the procedure on the study period. (data are expressed as mean ± standard deviation or number (percentage)). The 367 placements represent the placement in prone or supine positionsProne/Supine positioning placements, ***n*** (%) or mean ± SD (***n*** = 367)**Number of placements performed** Daily11.5 ± 3.4 First 2-day period7 ± 1.4 Acme 2-day period20 ± 4.2 Last 2-day period5 ± 0 Under VV-ECMO124 (34%)**Adverse events recorded during placements** **Major**  Cardiac arrest0  Unscheduled extubation0  Severe desaturation (SpO~2~ \< 85%)\*5 (1%) **Minor**  Accidental device removing or disconnection†6 (2%)\*Needing medical intervention†Minor: one epistaxis following accidental removing of naso-gastric tube, four incidental disconnections of ventilator lines, one incidental removing of central venous catheter

This specific medical team of trained non-intensivist volunteers was able to manage this delicate PP task without any major adverse events such as cardiac arrest or unscheduled extubation when compared to the relatively high incidence (respectively 6.8 and 13.3%) observed in Guérin et al. study \[[@CR1]\]. Our studied population was comparable to already published series of severe ARDS, and we found a similar mortality (26%) despite a lower initial P/F ratio and COVID-19 association \[[@CR1]\]. Interestingly, we recorded a greater survival rate than reported by Richardson et al. in the New York area at their edge of COVID-19 pandemic, but they did not detail the use of PP \[[@CR3]\].

This innovative management allowed three major benefits: (i) critical relief of permanent intensive care team's workload; (ii) reduction of the nurse-to-patient ratio, permitting also the reassignment of critical care nurses to newly created ICUs; and (iii) devoid of any self-censorship for fear of overwork and burn-out, intensivist physicians were able to strictly follow PP guideline recommendations, ensuring the best standard of care for ARDS patients.

Since the pathophysiology is poorly understood \[[@CR4], [@CR5]\], the specific role of PP among the optimal management for COVID-19 patients with ARDS, in order to reduce mortality needs to be addressed.
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